AKER News Alert Akers Biosciences (AKER) 3.20 12/25/2014 01:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Akers Biosciences (AKER) 3.20 $AKER

Akers Biosciences Signs European Distribution Agreements for PIFA Heparin PF4 Rapid Assay Products
GlobeNewswire - Thu Dec 18, 6:00AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company" , a leading designer and manufacturer of rapid diagnostic screening and testing products, has entered into its first European distribution agreements since the installment of its international vice president in August 2014. The Company has entered into multi-year distribution agreements for PIFA Heparin/PF4 Rapid Assay products with Cryopep SARL, covering France, Belgium, the Netherlands and Luxembourg; and DiaLine AG, covering Switzerland and Lichtenstein.
AKER: 3.20 (-0.10)

Dave Gentry Features Top 5 Healthcare Stocks for 2015 on This Week's RedChip Money Report on Fox Business and Bloomberg
GlobeNewswire - Tue Dec 16, 2:52PM CST
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" TM) television program will feature its top five healthcare companies for 2015 on Fox Business nationwide on Tuesday, December 16 at 10:00 p.m. Pacific (1 a.m. ET). The show will also air on Bloomberg Europe on Sunday, December 21 at 8:30 a.m. and 3:30 p.m. GMT; on Bloomberg U.K. Sunday, December 21 at 5:00 p.m. and 8:30 p.m. GMT; and on Bloomberg Asia on Sunday, December 21 at 3:30 p.m. HKT.
OPXA: 0.80 (+0.01), ATNM: 6.00 (-0.22), AKER: 3.20 (-0.10), CGIX: 7.12 (+0.06)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 11:45AM CST

ALOG: 86.43 (+0.32), VBIV: 3.06 (-0.14), PRTK: 37.70 (+1.30), TPLM: 5.74 (-0.41), MIND: 5.77 (+0.14), SSE: 6.64 (-0.03), ALLT: 9.28 (+0.15), EGY: 5.07 (+0.05), GBR: 1.28 (+0.10), ECTE: 1.50 (unch), PWE: 2.25 (+0.05), GDP: 4.93 (-0.22), LAYN: 10.11 (+0.25), WRES: 1.66 (-0.13), CALA: 22.33 (+1.16), AKER: 3.20 (-0.10), CVEO: 8.01 (-0.56), CNIT: 3.58 (+0.07), CYRN: 1.75 (+0.09), CRK: 7.01 (-0.20)

Akers Biosciences Announces $1 Million Initial Order to Supply PIFA Heparin/PF4 Products to China
GlobeNewswire - Wed Dec 10, 6:00AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company" , a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the receipt of an initial purchase order (the "Order" valued at US$1,000,000 from NovoTek Therapeutics Inc. ("NovoTek" to supply PIFA Heparin PF4/Rapid Assay products in Mainland China ("China" .
AKER: 3.20 (-0.10)

Update: My Discussion With RedChip And Thoughts Going Forward
Daniel Ward - at Seeking Alpha - Mon Dec 08, 8:08AM CST

XBI: 182.62 (+3.44), AKER: 3.20 (-0.10), AEZS: 0.59 (-0.02)

Cannabis (MMJ) Breathalyzer Could Follow Vertical Path of Alcohol Breathalyzer
ACCESSWIRE - Tue Dec 02, 8:40AM CST
Whitefish, MT / ACCESSWIRE / December 2, 2014 / The effects of alcohol on a driver are well documented, with motor skills and often decision-making skills decreasing with each drink, subsequently increasing the likelihood of a fatal accident. A field sobriety test (i.e. walking heel-to-toe, follow a pen with eyes, stand on one foot) typically does an ample job at helping police officers identify a driver under the influence of alcohol, which is then typically followed by the tried-and-true alcohol breathalyzer test to pinpoint blood alcohol concentration (BAC). Although some laws and penalties vary from state to state, there is a nationwide standard of drunk driving being defined as BAC at or above 0.08 percent. Technological advancements have made alcohol breathalyzers affordably available to businesses and consumers, like Akers Biosciences' (NASDAQ: AKER) CHUBE and BreathScan products, to estimate BAC. Another portable BAC estimator, Breathometer's eponymous device that operates by attaching it to the audio output of a smart phone, garnered an aggregate $1 million in investments from all five "sharks" in April on the popular CNBC show "Shark Tank," lending to the idea that it is a growing industry against the backdrop of stiffening laws and greater awareness. Breathometer isn't alone in the smart phone breathalyzer space, orders are being taken for FLOOME, a universal smartphone accessory for measuring BAC developed with the help of Proto Labs (NYSE: PRLB).
PRLB: 66.62 (-0.14), AKER: 3.20 (-0.10)

Horrendous Stock Performance Of RedChip Nation Healthcare And Biotech Stocks
Daniel Ward - at Seeking Alpha - Mon Dec 01, 10:29AM CST

INO: 9.11 (-0.09), AKER: 3.20 (-0.10)

RedChip Issues Research Update on Akers Biosciences
GlobeNewswire - Tue Nov 18, 7:40AM CST
RedChip Companies, Inc., today announced it has issued a research update on Akers Biosciences Inc. (Nasdaq:AKER), a leading designer and manufacturer of rapid diagnostic screening and testing products.
AKER: 3.20 (-0.10)

Akers Biosciences Net Loss of $1.12M
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:18AM CST

AKER: 3.20 (-0.10)

Akers Biosciences Announces Its Financial Results for Third Quarter 2014
GlobeNewswire - Thu Nov 13, 6:05AM CST
Akers Biosciences, Inc. (Nasdaq:AKER), (the "Company" or "ABI" , a leading designer and manufacturer of rapid diagnostic screening and testing products, reports its financial results for the third quarter ended September 30, 2014 and for the nine months ended September 30, 2014. The Form 10-Q containing the financial statements is available for viewing on the Company's website at www.akersbiosciences.com or www.sec.gov.
AKER: 3.20 (-0.10)

Akers Biosciences Announces Conference Call to Discuss Its Third Quarter and Nine Months Financial Results
GlobeNewswire - Mon Nov 10, 6:07AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company" or "ABI" , a leading designer and manufacturer of rapid diagnostic screening and testing products, will hold a conference call on Thursday, November 13, 2014, at 10:30 a.m. Eastern Time to discuss its results for the third quarter and nine months ended September 30, 2014.
AKER: 3.20 (-0.10)

The Perils Of Value Microcap Research And The Example Of Akers Biosciences
Daniel Ward - at Seeking Alpha - Tue Nov 04, 12:22PM CST

AKER: 3.20 (-0.10)

Week In Review: Roche Seeks China Partners With First-In-Class, Best-In-Class Products
ChinaBio Today - at Seeking Alpha - Sun Oct 26, 12:46PM CDT
Featured Companies In an exclusive interview, Dr. Darren Ji (Vice President and Global Head of Roche Partnering, Asia and Emerging Markets) told ChinaBio Today that Roche ( OTCQX:RHHBY ) ( OTCPK:RHHBF ) remains entirely focused on novel drugs for...
FMI: 23.99 (-0.10), AKER: 3.20 (-0.10), WX: 34.14 (+0.44)

Akers Biosciences Announces Joint Venture to Market Rapid Diagnostic Tests in China
GlobeNewswire - Thu Oct 23, 7:17AM CDT
Akers Biosciences, Inc. (Nasdaq:AKER) (LSE:AKR) (the "Company" or "Akers" , a leading designer and manufacturer of rapid diagnostic screening and testing products, has signed a Joint Venture Agreement (the "Joint Venture Agreement" with Hainan Savy Investment Management Ltd ("Hainan" and Mr. Thomas Knox ("Thomas Knox" , the Company's Non-executive Co-Chairman (Akers, Hainan and Thomas Knox together the "Parties" , to research, develop, produce and sell certain Akers' rapid diagnostic screening and testing products in China (the "Joint Venture" . The Joint Venture Company will be located in Haikou, the capital city of the province of Hainan, China, and is incorporated as Hainan Savy Akers Biosciences, Ltd.
AKER: 3.20 (-0.10), AKR: 32.96 (+0.11)

NETGEAR, Akers Biosciences, and TOP Ships to Appear on RedChip TV on Bloomberg
GlobeNewswire - Wed Oct 08, 10:46AM CDT
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" TM) television program is featuring interviews with NETGEAR (Nasdaq:NTGR), Akers Biosciences (Nasdaq:AKER), and TOP Ships (Nasdaq:TOPS) this week on Bloomberg television.
TOPS: 1.15 (+0.02), AKER: 3.20 (-0.10), NTGR: 36.00 (+0.15)

Akers Biosciences Features on Global Broadcast & Online Media
GlobeNewswire - Tue Sep 16, 11:45AM CDT
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that its Executive Chairman, Raymond F. Akers Jr., Ph.D, was featured on "The RedChip Money Report: Small Stocks Big Money" television program which was televised on Fox Business nationwide as well as Bloomberg Europe, UK and Asia. A recording of the globally transmitted interview regarding Akers Biosciences' business can be viewed here: http://youtu.be/5ymviBu1kno.
AKER: 3.20 (-0.10)

Police and Employers May Finally See Cannabis Breathalyzer
ACCESSWIRE - Wed Sep 10, 8:47AM CDT
Whitefish, MT / September 10, 2014 / The gradual proliferation of alcohol breathalyzer technology has helped bring down the per unit price so far that professional-grade technology, like the kind developed by Akers Biosciences, Inc. (NASDAQ: AKER), is now being marketed directly to consumers. Touted as a safety measure, as well as a means of avoiding the high cost and complications of a DUI/DWI, alcohol breathalyzers are becoming a proactive tool, used by consumers to help them more confidently enjoy an intoxicating product on their own terms.
AKER: 3.20 (-0.10), BED.VN: 0.750 (-0.040), TWD.VN: 2.000 (-0.020)

RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Tue Sep 09, 1:34PM CDT
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" TM) television program will feature three companies on Fox Business nationwide on Tuesday, September 9 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg Europe on Sunday, September 14 at 8:30 a.m. and 3:30 p.m. GMT; on Bloomberg U.K. Sunday, September 14 at 5:00 p.m. and 8:30 p.m. GMT; and on Bloomberg Asia on Sunday September 14 at 3:30 p.m. HKT.
IQNT: 18.30 (-0.07), AKER: 3.20 (-0.10)

Akers Biosciences Presenting at US Investor Conferences
GlobeNewswire - Tue Sep 09, 12:43PM CDT
Executive Chairman Raymond F. Akers Jr., Ph.D, to present at:
AKER: 3.20 (-0.10)

Akers Biosciences Announces $864,000 Sales Contract for Its Rapid Results Point of Care Cholesterol Test
GlobeNewswire - Tue Sep 09, 6:30AM CDT
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company" or "ABI" , a leading designer and manufacturer of rapid diagnostic screening and testing products, announced a contract valued at $864,000 for sales of its innovative Tri-Cholesterol "Check" tests in Australia, Singapore, the United Arab Emirates and Oman. The Company's products are being distributed in such regions by 36 Strategies General Trading LLC ("36S" , a Dubai-based procurement solutions company. Target customers in Australia, Singapore, the United Arab Emirates and Oman include military forces, medical associations, universities and large companies operating in the resources sector.
AKER: 3.20 (-0.10)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Human Frontier Mission Puts AI Research on Display

Updated Category News Views 45

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 182

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 121

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 105

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 104

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 140

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 98

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 97

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Stellantis NV: Short Interest Shift Sparks Investor Sentiment Questions

Updated Category News Views 299

Stellantis NV's (NYSE:STLA) short interest saw a notable drop of 13.81% since its last report, now standing at 44.96 million shares sold short, or about 1.56% of all tradable shares. Sounds like good news, right? But hang on—this isn't just a free pass to pop the champagne. When we talk short interest, we're peeling back layers on market sentiment that can turn on a...

Continue Reading
Minerals Technologies Showcases Innovative PFAS Solutions at Symposium

Updated Category News Views 185

Minerals Technologies to Present at Gabelli Funds PFAS Symposium Minerals Technologies Inc. (MTI) is thrilled to announce its participation in the upcoming PFAS Symposium hosted by Gabelli Funds. This notable event is set to take place in New York City, bringing together key figures in the industry to discuss significant advancements and novel strategies for tackling...

Continue Reading
Morning Market Insights for Key Stocks: A Daily Review

Updated Category News Views 338

Daily Market Insights: Leading Stocks to Watch Good morning, traders. Today’s notes zero in on SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA—names that tend to steer the broader tape. Our read on price comes from a blend of key levels shaped by price action, trading volume, and options flow. We refresh these levels daily and share them with Market Clubhouse...

Continue Reading
Exploring the Evolving Landscape of Electric Vehicles in the U.S.

Updated Category News Views 224

The Current State of Electric Vehicles in the U.S. The electric vehicle (EV) landscape in the U.S. is experiencing transformative changes. As the country marks significant milestones in EV deployment, there are noteworthy gaps in infrastructure and consumer attitudes that need addressing. The third annual HERE-SBD EV Index reveals how far the U.S. has come, yet highlights...

Continue Reading
eBay's Legal Victory: Dismissal of Harmful Product Claims

Updated Category News Views 173

eBay's legal drama hit the news when the U.S. government slammed them with a lawsuit accusing the online giant of violating the Clean Air Act back in 2024. The crux? Selling products that supposedly helped folks skirt around those pesky auto pollution controls. You know how it is—desks buzzing about regulatory risks, and traders getting twitchy over such moves. The...

Continue Reading